万泰生物: 万泰生物高级管理人员集中竞价减持股份结果公告

Summary of Key Points Core Viewpoint - The announcement details the results of a share reduction plan executed by a senior management member of Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., specifically Vice President Zhao Lingzhi, who has reduced her shareholding in the company. Group 1: Shareholding Information - As of the disclosure date of the reduction plan (December 21, 2024), Zhao Lingzhi held 1,695,308 shares, representing 0.1340% of the company's total share capital, with these shares being unrestricted and acquired prior to the company's IPO and through dividend distributions from 2020 to 2022 [1][2][3]. Group 2: Reduction Plan Implementation Results - Zhao Lingzhi has completed her share reduction plan, having sold a total of 400,000 shares through centralized bidding, which accounts for 0.0316% of the total shares. Following this reduction, her remaining shareholding is 1,295,308 shares, or 0.1024% of the total share capital [1][2][3]. - The total amount from the reduction was 27,150,812 yuan, confirming that the actual reduction met the previously disclosed plan [2][3].